Lead Product(s) : Fluconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Gets USFDA Nod to Market Generic Antifungal Tablets
Details : Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration, which is indicated for the treatment of Vaginal candidiasis.
Brand Name : Diflucan-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 25, 2023
Lead Product(s) : Fluconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fluconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Undisclosed
Deal Size : $3.0 million
Deal Type : Acquisition
ANI Pharmaceuticals Announces Acquisition of Fluconazole Tablets
Details : ANI Pharmaceuticals acquired Fluconazole Tablets USP, 50mg, 100mg, 150mg, and 200mg. Fluconazole Tablets USP is indicated for the treatment of vaginal candidiasis (vaginal yeast infections due to Candida) and oropharyngeal and esophageal candidiasis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 06, 2020
Lead Product(s) : Fluconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Undisclosed
Deal Size : $3.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
